Drive innate immune therapies forward with our genO-hcGAS & genO-hSTING models

genOway’s mouse models enable a translatable in vivo efficacy testing of therapies targeting the cGAS-STING pathway

‍

What sets the genO-hcGAS mouse model apart?

Key features:

• Physiological regulation and expression of human cGAS
• Fully functional mouse immune system
• Lack of expression of the murine target gene

‍

The genO-hcGAS mouse was used to test the efficacy of a cGAS agonist and cytokine production was observed.

‍

Treatment with a cGAS agonist leads to cytokine secretion in genO-hcGAS mice

‍

‍

‍

What sets the genO-hSTING mouse model apart?

Key features:

• Physiological regulation of the human STING
• Fully functional mouse immune system
• Lack of expression of the murine target gene
• Different versions of genO‑hSTING models are available (expressing different variants):

Curadev used the genO-hSTING mouse to test the efficacy of CRD5500, a STING agonist, for inhibiting pancreatic cancer development and observed tumor growth inhibition:

‍

Efficacy assessment of a STING agonist in genO-hSTING mice

‍

‍

Adapted from Curadev's AACR 2022 poster, Banerjee et al.

‍

The double-humanized genO-hcGAS/hSTING mouse model

The upgraded genO-hcGAS/hSTING mouse model resulting from the intercrossing of the genO-hcGAS and genO-hSTING models will be available in 2026, offering increased translatability.